Pulse Biosciences partners with Clayman Thyroid Center to commercialize Vybrance for benign thyroid nodules

Pulse Bio (PLSE) reported Q3 2026 earnings, highlighting completion of Nano-Pulse AF study enrollment ahead of schedule with 169 evaluable patients. The company has $189M in cash, supporting operations for two years. Pulse Bio's nPulse cardiac catheter system showed rapid adoption and positive feedback from physicians, with potential transformative impact. The company expects final data in Q3 2027 and CE Mark approval in Q4 2027.

Pulse Biosciences reported 86% of patients in its PRECISE-BTN study achieved at least 50% thyroid nodule volume reduction at six months, with a median reduction of 72%. Quality of life scores improved 78%, and 82% of patients saw resolution of neck pressure or fullness. No serious adverse events were reported. The company plans to release more data as follow-up continues.

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting 86% of patients evaluated achieved at least 50% nodule volume reduction at six months after a single nonthermal nsPFA treatm

Pulse Biosciences (PLSE) reported interim results from its PRECISE-BTN study, showing 86% of patients achieved at least 50% nodule volume reduction at six months. The median volume reduction was 72%, with no serious adverse events. The company expects to report data for all patients at six and 12 months.

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results Completed enrollment of NANOPULSE-AF US IDE pivotal study for treatment of AF with nPulse Cardiac Catheter System Ended the quarter with $189 million of cash, cash equivalents, and ma

Pulse Biosciences (PLSE) completed enrollment for its NANOPULSE-AF study, meeting its target of 164 patients across 15 sites. The study aims to assess the safety and effectiveness of its nPulse Cardiac Catheter System for drug-resistant atrial fibrillation. Analysts forecast revenue of $38.3M and earnings of $4.8M by 2029, with significant growth and earnings swing expected. The trial's outcomes will influence regulatory, reimbursement, and commercialization decisions.